LivaNova PLC Ordinary Shares LIVN
i
Market dataready · fetched 2026-11-04T02:51:21.009Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T21:00:02.276605102Z
FundamentalsSEC EDGAR · ready · as of 2026-06-30 · fetched 2026-11-04T02:51:20.563957+00:00
LivaNova PLC Ordinary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 91.97 | 69.4% | 16.6% | 71.09 | 72.1% | 12.9% |
| 25Δ | 88.37 | 61.5% | 12.5% | 73.39 | 66.5% | 10.4% |
| 30Δ | 86.40 | 59.6% | 10.4% | 75.22 | 63.1% | 8.7% |
| 35Δ | 84.77 | 59.0% | 8.9% | 76.64 | 63.2% | 7.6% |
| 40Δ | 83.33 | 58.2% | 7.6% | 78.03 | 62.1% | 6.5% |
| 45Δ | 81.96 | 58.7% | 6.6% | 79.37 | 59.2% | 5.3% |
| 50Δ | 80.71 | 61.0% | 5.9% | 80.64 | 57.1% | 4.4% |
| 55Δ | 79.37 | 64.2% | 5.3% | 81.85 | 55.9% | 3.7% |
| 60Δ | 77.91 | 68.6% | 4.8% | 83.00 | 54.1% | 3.0% |
| 65Δ | 76.43 | 68.8% | 4.0% | 84.08 | 51.9% | 2.3% |
| 70Δ | 74.94 | 67.5% | 3.2% | 85.19 | 49.8% | 1.7% |
| 75Δ | 73.20 | 68.6% | 2.6% | 86.43 | 48.5% | 1.3% |
| 80Δ | 71.27 | 69.7% | 2.0% | 87.69 | 47.2% | 0.9% |
20Δ
- Pseudo strike
- 91.97
- IV
- 69.4%
- B/E move
- 16.6%
- Pseudo strike
- 71.09
- IV
- 72.1%
- B/E move
- 12.9%
25Δ
- Pseudo strike
- 88.37
- IV
- 61.5%
- B/E move
- 12.5%
- Pseudo strike
- 73.39
- IV
- 66.5%
- B/E move
- 10.4%
30Δ
- Pseudo strike
- 86.40
- IV
- 59.6%
- B/E move
- 10.4%
- Pseudo strike
- 75.22
- IV
- 63.1%
- B/E move
- 8.7%
35Δ
- Pseudo strike
- 84.77
- IV
- 59.0%
- B/E move
- 8.9%
- Pseudo strike
- 76.64
- IV
- 63.2%
- B/E move
- 7.6%
40Δ
- Pseudo strike
- 83.33
- IV
- 58.2%
- B/E move
- 7.6%
- Pseudo strike
- 78.03
- IV
- 62.1%
- B/E move
- 6.5%
45Δ
- Pseudo strike
- 81.96
- IV
- 58.7%
- B/E move
- 6.6%
- Pseudo strike
- 79.37
- IV
- 59.2%
- B/E move
- 5.3%
50Δ
- Pseudo strike
- 80.71
- IV
- 61.0%
- B/E move
- 5.9%
- Pseudo strike
- 80.64
- IV
- 57.1%
- B/E move
- 4.4%
55Δ
- Pseudo strike
- 79.37
- IV
- 64.2%
- B/E move
- 5.3%
- Pseudo strike
- 81.85
- IV
- 55.9%
- B/E move
- 3.7%
60Δ
- Pseudo strike
- 77.91
- IV
- 68.6%
- B/E move
- 4.8%
- Pseudo strike
- 83.00
- IV
- 54.1%
- B/E move
- 3.0%
65Δ
- Pseudo strike
- 76.43
- IV
- 68.8%
- B/E move
- 4.0%
- Pseudo strike
- 84.08
- IV
- 51.9%
- B/E move
- 2.3%
70Δ
- Pseudo strike
- 74.94
- IV
- 67.5%
- B/E move
- 3.2%
- Pseudo strike
- 85.19
- IV
- 49.8%
- B/E move
- 1.7%
75Δ
- Pseudo strike
- 73.20
- IV
- 68.6%
- B/E move
- 2.6%
- Pseudo strike
- 86.43
- IV
- 48.5%
- B/E move
- 1.3%
80Δ
- Pseudo strike
- 71.27
- IV
- 69.7%
- B/E move
- 2.0%
- Pseudo strike
- 87.69
- IV
- 47.2%
- B/E move
- 0.9%
Options history
Table
| Date | IV (%) |
|---|---|
| 40.52% | |
| 40.04% | |
| 39.55% | |
| 40.45% | |
| 38.17% | |
| 37.51% | |
| 36.80% | |
| 37.64% | |
| 40.70% | |
| 41.92% | |
| 40.41% | |
| 36.30% | |
| 37.96% | |
| 37.39% | |
| 37.23% | |
| 36.57% | |
| 36.81% | |
| 35.77% | |
| 35.64% | |
| 35.83% | |
| 35.30% | |
| 35.62% | |
| 38.75% | |
| 38.91% | |
| 39.63% | |
| 38.42% | |
| 38.98% | |
| 42.28% | |
| 46.40% | |
| 37.48% | |
| 38.79% | |
| 40.50% | |
| 40.50% | |
| 40.17% | |
| 40.88% | |
| 37.99% | |
| 39.12% | |
| 39.20% | |
| 38.32% | |
| 38.91% | |
| 40.46% | |
| 40.65% | |
| 41.70% | |
| 41.27% | |
| 43.84% | |
| 41.33% | |
| 46.75% | |
| 50.93% | |
| 49.92% | |
| 41.05% | |
| 40.51% | |
| 39.16% | |
| 40.26% | |
| 39.76% | |
| 42.10% | |
| 42.37% | |
| 42.23% | |
| 41.51% | |
| 40.18% | |
| 42.87% |
Medical Devices
LNSR
LENSAR, Inc., a commercial stage medical device company, is focused on designing, developing and marketing an advanced femtosecond laser system for the treatment of cataracts and…
More →LUNG
Pulmonx Corporation, a medical technology company, designs, develops, manufactures and markets minimally invasive medical devices for the diagnosis and treatment of chronic…
More →MASS
908 Devices Inc. develops and sells measuring devices for chemical and biochemical analysis in North America, Europe, the Middle East, Africa, and Asia Pacific. The company is…
More →MBOT
Description unavailable
More →MDT
Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in…
More →MXCT
MaxCyte Inc. (MXCT) is a leader in cell-engineering, renowned for its innovative Flow Electroporation® technology that enables efficient and scalable delivery of nucleic acids and…
More →